Promising new combo tackles advanced stomach cancer in early trial
NCT ID NCT07315854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of two experimental drugs (iparomlimab and tuvonralimab, together called QL1706) plus standard chemotherapy in people with advanced stomach or gastroesophageal junction cancer that hasn't been treated before. The goal is to see if this combo can shrink tumors and how safe it is. About 32 participants will receive the treatment every 3 weeks, with maintenance therapy after 6 cycles.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100050, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Experimental drug TJ037130 takes aim at advanced solid tumors
- Electric acupoint therapy may speed digestion and ease pain after stomach cancer surgery
- New imaging tracer could spot hidden cancers and fibrosis in one scan